Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Old oak trees and semi-natural grasslands are very important for a large number of species that risk disappearing as habitats decline. In a new study, researchers at Linköping University in Sweden ...

Most security teams think of NTFS junctions and symbolic links as niche file system features. They let one directory point to another, like a shortcut that the OS treats as real. They exist for ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

Anthropic reveals that Claude now writes over 80% of its production code, with engineers shipping 8x more code per quarter than in 2024. The company’s new Anthropic Institute paper maps the path to ...

They say everyone is related in a small town, and in Rio Paloma, Texas, that might be true. Dutton Ranch's fictional setting requires a brief lesson in genealogy to keep up with alliances and feuds.

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

World No. 4 Coco Gauff appreciates how tennis differentiates itself from other sports. Specifically, how “literally it's not over until it's over” with players needing to reach—and then close ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...